Providers

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration, prompted by growing interest in its use as a predictive biomarker for HF.

The increased use of technology in the classrooms has forced ophthalmologists, optometrists, and educators to consider the perfect balance in children’s development.

Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.

There may be a small, but not overwhelming, benefit for certain individuals aged 40 to 59 years who have a slightly elevated risk of future cardiovascular disease (CVD) to start taking aspirin, according to an update released by the US Preventive Services Task Force (USPSTF).

Elevated prevalence of post-traumatic stress disorder seen in family members of patients with COVID-19 treated in intensive care units; 9 rare respiratory cancers linked with burn pit exposure among veterans; adenovirus suggested as potential cause of unexplained cases of pediatric hepatitis.

A simple score can identify the patients at risk of severe infection within 4 months of initiating treatment, highlighting candidates to be treated with prophylactic antibiotics.

Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack of public and physician awareness on disease burden and poor sleep quality.

This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion (CSII) or a basal-bolus regimen.

By creating a framework for social determinants of health that explores patients’ needs and prioritizes team members’ response, specialty practices can more effectively strengthen health equity, access to care, and health outcomes.

A decade’s worth of data included more than 5 million social determinants of health (SDOH) attributes across nearly 2 million clinical notes from the patient visits extrapolated from a natural language processing system.

To mark the nation's 52nd Earth Day, Robert Feder, MD, outlines how climate change will exacerbate mental health challenges and the importance of global efforts to address the crisis.

Patients with reduced DNA mismatch repair protein expression were more likely to respond to immune checkpoint inhibitors (ICIs), although this study had a small sample size.

A combination of biology, access issues, and delayed diagnoses have contributed to disparities experienced by Black women with metastatic breast cancer, explained Hatem Soliman, MD, medical director of the Clinical Trials Office, Moffitt Cancer Center.

Interviewing both patients and providers, researchers found that while having effective treatments for hidradenitis suppurativa (HS) took precedence across the board, some priorities varied among the 2 groups.

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.

Key opinion leaders addressed cost, accessibility, and other barriers limiting use of comprehensive genomic profiling (CGP), and how employers can help drive preventive care and precision medicine through CGP.

The lack of effective long-term control of eosinophilic esophagitis (EoE) highlights the unmet need for targeted systemic therapies.

The frequency of global crises such as hurricanes, war, and the pandemic makes a standing committee necessary.

Patients who received early immunosuppressive therapy for their rheumatoid arthritis (RA)–associated peripheral ulcerative keratitis experienced earlier inflammatory control, fewer recurrences, and better visual outcomes.

Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades.

Expression of the chemokine receptor was linked with better overall survival.

Patients may have unrealistic expectations of how a new treatment or procedure may help them, and the conversation between the patient and physician is crucial for setting expectations, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

Predictive models can help find high-risk patients with asthma and manage them proactively, but prior models miss the highest-risk patients and may mislabel low-risk patients.

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022.

This new literature review explored the potential to enhance management for type 1 diabetes (T1D) through the adoption of physiological parameters measured by wearable and sensor-enabled health-related technology.